DXCM: Dexcom Company Sales Revenue

DexCom, Inc. (DXCM) leads the CGM segment, penetrating niches for non-diabetics. Growth is driven by the scaling of G7 and the expansion of insurance coverage. The defensive nature of the business ensures stability during a recession, as confirmed by the company's sales revenue. On this chart, the 5.10 mark serves as a key metric capturing the current dynamics of sales cash inflows.

Revenue and Sales Volume: Dexcom (DXCM) for 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Dexcom (DXCM)

- stock value and consensus price forecast:

Stock Quotes Dexcom CGM|DXCM - Consensus Target

- market capitalization information:

Market Value DexCom, Inc.|DXCM - Total Company Value

- balance sheet net asset value indicators:

Accounting Value per Share Dexcom|DXCM - Book Capitalization|Market-to-Book Ratio dexcom.com|DXCM - Company Total Assets

- company liabilities and liquidity data:

- company profitability and valuation multiples indicators:

DXCM - Net Income|Expected Net Income DexCom, Inc.|DXCM - P/E Multiple|Projected Price to Earnings Ratio dexcom.com|DXCM - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Multiple DexCom, Inc.|DXCM - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Dexcom|DXCM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months dexcom.com|DXCM - Earnings per share growth in current year|Net earnings per share change forecast for next year DexCom, Inc.

- company sales and revenue statistics:

DXCM - Company Revenue|Company Future Sales Volume Dexcom CGM|DXCM - P/S Multiple|Market Cap to Future Revenue Ratio DexCom, Inc.

Summary company analysis:DXCM Dexcom CGM

DexCom, Inc. (DXCM) holds a leading position in the non-cyclical medical technology segment. By analyzing the company's sales volume dynamics, an investor can see the actual value of products sold per day. This indicator captures the real-time deviation of operating results from planned targets. Stable demand for glucose monitoring makes this metric resilient to macroeconomic fluctuations, and the market views such growth as the foundation for long-term capitalization.

Key competitors